LncRNA MCTP1-AS1 Regulates EMT Process in Endometrial Cancer by Targeting the miR-650/SMAD7 Axis

References

• McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother’s cancer. Cancer. 2016;122:2787–2798. doi:10.1002/cncr.30094
   PubMed Web of Science ®Google Scholar
• Chang Z, Talukdar S, Mullany SA, Winterhoff B. Molecular characterization of endometrial cancer and therapeutic implications. Curr Opin Obstet Gynecol. 2019;31:24–30. doi:10.1097/GCO.0000000000000508
   PubMed Web of Science ®Google Scholar
• Lee YC, Lheureux S, Oza AM. Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol. 2017;29:47–58. doi:10.1097/GCO.0000000000000338
   PubMed Web of Science ®Google Scholar
• Braun MM, Overbeek-wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016;93:468–474.
   PubMed Web of Science ®Google Scholar
• Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–3981. doi:10.1158/0008-5472.CAN-16-2634
   PubMed Web of Science ®Google Scholar
• Akhade VS, Pal D, Kanduri C. Long noncoding RNA: genome organization and mechanism of action. Adv Exp Med Biol. 2017;1008:47–74. doi:10.1007/978-981-10-5203-3_2
   PubMed Web of Science ®Google Scholar
• Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA interactions. Methods Mol Biol. 2016;1402:271–286. doi:10.1007/978-1-4939-3378-5_21
   PubMedGoogle Scholar
• Yang X, Yan Y, Chen Y, Li J, Yang J. Involvement of NORAD/miR-608/STAT3 axis in carcinostasis effects of physcion 8-O-beta-glucopyranoside on ovarian cancer cells. Artif Cells Nanomed Biotechnol. 2019;47:2855–2865. doi:10.1080/21691401.2019.1637884
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Y, Sona L. Long non-coding RNA RP11-480I12.5 promotes cervical carcinoma progression by regulating the Wnt/beta-catenin signaling pathway. Oncol Lett. 2020;19:469–475. doi:10.3892/ol.2019.11120
   PubMed Web of Science ®Google Scholar
• Wang XY, Qin YY. Long non-coding RNAs in biology and female reproductive disorders. Front Biosci. 2019;24:750–764. doi:10.2741/4748
   Web of Science ®Google Scholar
• Xie P, Cao H, Li Y, Wang J, Cui Z. Knockdown of lncRNA CCAT2 inhibits endometrial cancer cells growth and metastasis via sponging miR-216b. Cancer Biomark. 2017;21:123–133. doi:10.3233/CBM-170388
   PubMed Web of Science ®Google Scholar
• Shao W, Li Y, Chen F, et al. Long non-coding RNA DLEU1 contributes to the development of endometrial cancer by sponging miR-490 to regulate SP1 expression. Pharmazie. 2018;73:379–385. doi:10.1691/ph.2018.8352
   PubMed Web of Science ®Google Scholar
• Sun KX, Wu DD, Chen S, Zhao Y, Zong ZH. LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway. Apoptosis. 2017;22:1543–1552. doi:10.1007/s10495-017-1426-7
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang J, Jiang A, et al. Expression profile of long non-coding RNAs is altered in endometrial cancer. Int J Clin Exp Med. 2015;8:5010–5021.
   PubMed Web of Science ®Google Scholar
• Ratner ES, Tuck D, Richter C, et al. MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol. 2010;118:251–257. doi:10.1016/j.ygyno.2010.05.010
   PubMed Web of Science ®Google Scholar
• Han LL, Yin XR, Zhang SQ. miR-650 promotes the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by directly inhibiting LATS2 expression. Cell Physiol Biochem. 2018;51:1179–1192. doi:10.1159/000495495
   PubMedGoogle Scholar
• Orlandella FM, Mariniello RM, Iervolino PLC, et al. miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA. Endocrine. 2019;65:582–594. doi:10.1007/s12020-019-01910-3
   PubMed Web of Science ®Google Scholar
• Reguly T, Wrana JL. In or out? The dynamics of Smad nucleocytoplasmic shuttling. Trends Cell Biol. 2003;13:216–220. doi:10.1016/S0962-8924(03)00075-8
   PubMed Web of Science ®Google Scholar
• Javelaud D, Mauviel A. Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles. Int J Biochem Cell Biol. 2004;36:1161–1165. doi:10.1016/S1357-2725(03)00255-3
   PubMed Web of Science ®Google Scholar
• Parikh A, Lee C, Joseph P, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 2014;5:2977. doi:10.1038/ncomms3977
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhu W, Zhang J, et al. MicroRNA-650 targets ING4 to promote gastric cancer tumorigenicity. Biochem Biophys Res Commun. 2010;395:275–280. doi:10.1016/j.bbrc.2010.04.005
   PubMed Web of Science ®Google Scholar
• Zeng ZL, Li FJ, Gao F, Sun DS, Yao L. Upregulation of miR-650 is correlated with down-regulation of ING4 and progression of hepatocellular carcinoma. J Surg Oncol. 2013;107:105–110. doi:10.1002/jso.23210
   PubMed Web of Science ®Google Scholar
• You Q, Li H, Liu Y, et al. MicroRNA-650 targets inhibitor of growth 4 to promote colorectal cancer progression via mitogen activated protein kinase signaling. Oncol Lett. 2018;16:2326–2334. doi:10.3892/ol.2018.8910
   PubMed Web of Science ®Google Scholar
• Zuo Z-H, Yu YP, Ding Y, et al. Oncogenic activity of miR-650 in prostate cancer is mediated by suppression of CSR1 expression. Am J Pathol. 2015;185:1991–1999. doi:10.1016/j.ajpath.2015.03.015
   PubMed Web of Science ®Google Scholar
• Kharma B, Baba T, Matsumura N, et al. STAT1 drives tumor progression in serous papillary endometrial cancer. Cancer Res. 2014;74:6519–6530. doi:10.1158/0008-5472.CAN-14-0847
   PubMed Web of Science ®Google Scholar
• Kaczorowski M, Biecek P, Donizy P, et al. SMAD7 is a novel independent predictor of survival in patients with cutaneous melanoma. Transl Res. 2019;204:72–81. doi:10.1016/j.trsl.2018.09.002
   PubMed Web of Science ®Google Scholar
• Yan X, Liao H, Cheng M, et al. Smad7 protein interacts with receptor-regulated Smads (R-Smads) to inhibit transforming growth factor-beta (TGF-beta)/Smad signaling. J Biol Chem. 2016;291:382–392. doi:10.1074/jbc.M115.694281
   PubMed Web of Science ®Google Scholar
• Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601–609. doi:10.1172/JCI12821
   PubMed Web of Science ®Google Scholar
• Lan HY. Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci. 2008;13:4984–4992. doi:10.2741/3057
   PubMed Web of Science ®Google Scholar
• Xu J, Xu Y. The lncRNA MEG3 downregulation leads to osteoarthritis progression via miR-16/SMAD7 axis. Cell Biosci. 2017;7:69. doi:10.1186/s13578-017-0195-x
   PubMed Web of Science ®Google Scholar